Search Results

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external experts found that the company did not provide enough data to support its drug application.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024.

Lexicon Pharmaceuticals, Inc. announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following multiple interactions with and recent feedback from the U.S. Food and Drug Administration (FDA), it has resubmitted its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in people with type 1 diabetes and chronic kidney disease (CKD).

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III trials before long.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2024 and provided an update on key corporate milestones.